Cadrenal Therapeutics, Inc. Common Stock
CVKD
$-0.24
Change (1 day)
$32.55
Year High
$5.40
Year Low
Categories
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
P/B ratio for Cadrenal Therapeutics, Inc. Common Stock (CVKD)
P/B ratio as of 2023: 19.47
According to Cadrenal Therapeutics, Inc. Common Stock's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 19.47. At the end of 2022 the company had a P/B ratio of -8.64.
P/B ratio history for Cadrenal Therapeutics, Inc. Common Stock from 2022 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 19.47 |
| 2022 | -8.64 |